Status: Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Participants needed: 202
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Abbisko Therapeutics Co, LtdUpdated: Nov 19, 2024Locations: 21
Eligibility criteria
Patients must have the a central laboratory or previous test report confirming F... [+18]
Previous treatment with an FGFR pathway inhibitor or a multi-kinase inhibitor de... [+7]